We are live on ! Find out more

Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
ACRV icon
376
Acrivon Therapeutics
ACRV
$91.3M
$91.3M $2.13 3.4%
VRCA icon
377
Verrica Pharmaceuticals
VRCA
$91M
$91M $5.30 1.12%
FBIO icon
378
Fortress Biotech
FBIO
$90.7M
$90.7M $2.72 0.37%
ICCC icon
379
ImmuCell
ICCC
$89.9M
$89.9M $9.90 1%
RLYB icon
380
Rallybio
RLYB
$89.9M
$89.9M $16.93 0.3%
ACET icon
381
Adicet Bio
ACET
$89.8M
$89.8M $9.59 1.7%
ALDX icon
382
Aldeyra Therapeutics
ALDX
$89.3M
$89.3M $1.48 0%
GOSS icon
383
Gossamer Bio
GOSS
$85.7M
$85.7M $0.1753 0.17%
CRDF icon
384
Cardiff Oncology
CRDF
$84.8M
$84.8M $1.09 0.93%
IBIO icon
385
iBio
IBIO
$84.2M
$84.2M $1.31 0.77%
ATHE
386
Alterity Therapeutics
ATHE
$82.7M
$82.7M $4.54 0.44%
OKYO
387
OKYO Pharma
OKYO
$82.4M
$82.4M $1.57 1.29%
YARW
388
Yarrow Bioscience
YARW
$80.7M
$80.7M $30.21 4.71%
MNOV icon
389
MediciNova
MNOV
$80.2M
$80.2M $1.63 0.62%
TELO icon
390
Telomir Pharmaceuticals
TELO
$79.8M
$79.8M $1.16 0%
APLM icon
391
Apollomics
APLM
$79.6M
$79.6M $27.50 1.82%
GANX icon
392
Gain Therapeutics
GANX
$78.6M
$78.6M $1.80 1.1%
DWTX
393
Dogwood Therapeutics
DWTX
$77.8M
$77.8M $2.29 2.97%
RNTX
394
Rein Therapeutics
RNTX
$76.7M
$76.7M $0.8891 5.39%
CING icon
395
Cingulate
CING
$74.2M
$74.2M $5.10 2.3%
CSBR icon
396
Champions Oncology
CSBR
$72.7M
$72.7M $5.22 1.14%
TENX icon
397
Tenax Therapeutics
TENX
$72.6M
$72.6M $1.94 8.99%
NTRB icon
398
Nutriband
NTRB
$72.6M
$72.6M $5.97 6.04%
PLRX icon
399
Pliant Therapeutics
PLRX
$71.8M
$71.8M $1.16 2.65%
LONA
400
LeonaBio Inc
LONA
$71.2M
$71.2M $7.56 1.82%
14 15
16
17 18

Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 568 Biotechnology industry stocks tracked by Wall St. Rank, worth a combined $1.35T.

The largest by market cap are Vertex Pharmaceuticals (VRTX) at $138B, Regeneron Pharmaceuticals (REGN) at $85.2B and argenx (ARGX) at $64.6B.

Among institutional investors, Revolution Medicines (RVMD) drew the most net new fund positions in Q2 2026: 243 funds opened new positions, taking total fund holders up 177 (34%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.